Seeking Alpha

Dynavax Technologies (DVAX +3%) moves up with the overall market today, shrugging off a...

Dynavax Technologies (DVAX +3%) moves up with the overall market today, shrugging off a less-than-stellar initiation at JPMorgan with a Neutral rating. The firm cites certain regulatory risks associated with DVAX's hepatitis B vaccine Heplisav. The stock dropped 47% in November after the FDA panel gave its decision that the drug's safety data was inadequate. Heplisav is an adjuvant vaccine that regulators say might cause autoimmune diseases.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|